Today, Fool.com health-care analysts David Williamson and Max Macaluso look at what investors need to know about Biogen's potential blockbuster drug BG-12.
It looks as if investors will have to wait a little longer, as the drug has been delayed. Shares are down only moderately on the news, and investors really shouldn't be too worried. David explains why this isn't as bad as it seems, and why this drug could still be one of the biggest blockbusters ever.
